Asset profile

elasomeran · Spikevax

Vaccine

Approved / Phase 4Mechanism not established
Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Approvedregulatory verdict

Evidence outlook

Approved: COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
December 2026 (1)
Phase 4SARS-CoV-2Recruiting
Est. primary completion 2026-12-31 · NCT06585241 · CT.gov ↗
What to watch
Unlock with Research ↗
2027 (1)
June 2027 (1)
Phase 4SARS-CoV-2Active not recruiting
Est. primary completion 2027-06-16 · NCT07266558 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 3 (12)
Phase 2/3 (4)
Phase 2 (11)
Phase 1/2 (4)
Phase 1 (5)
Phase 4 (9)
Early phase / not applicable (1)
Used as active comparator (8)
Appears in other studies (4)